Menu Close

Study finds cilostazol is well tolerated but doesn’t prevent cognitive decline

A recent study demonstrated the safety of cilostazol in patients with mild cognitive impairment (MCI), but did not demonstrate any efficacy in preventing disease progression. However, after administration of cilostazol, the blood concentrations of the albumin and β-amyloid complex (albumin-Aβ complex) increased in the treated patients compared with those receiving placebo.